⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
prnewswire.com
VNDA
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
ANVS
SUPN
ABBV
VNDA
JAZZ
ACAD
MRK
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
prnewswire.com
VNDA
Revolutionizing Cancer Treatment: Global Microbiome Oncology Market Set to Surge at 40.7% CAGR, Reaching $1.94 Billion by 2031
globenewswire.com
VNDA
Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
prnewswire.com
JNJ
VNDA
PFE
MRK
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
prnewswire.com
VNDA
Tradipitant Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
globenewswire.com
VNDA